Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LaFleur Minerals Provides Update on Beacon Mill Restart and Exploration Updates (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Mersana Therapeutics Inc MRSN

Healthcare Biotechnology
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is focused on the development of antibody-drug conjugates (ADCs), which offer a clinically meaningful benefit for cancer patients with significant unmet needs. It has developed two proprietary and differentiated ADC platforms: Dolasynthen and Immunosynthen. Dolasynthen is a cytotoxic ADC platform that is designed to... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:MRSN)

Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2024 Financial Results

GlobeNewswire March 3, 2025

Mersana Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire February 25, 2025

Mersana Therapeutics to Host Fourth Quarter and Year End 2024 Conference Call on March 3, 2025

GlobeNewswire February 24, 2025

Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire February 7, 2025

Mersana Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference

GlobeNewswire January 30, 2025

Mersana Therapeutics Announces Additional FDA Fast Track Designation Granted to Emiltatug Ledadotin (XMT-1660)

GlobeNewswire January 10, 2025

Mersana Therapeutics Announces Positive Initial Clinical Data from Phase 1 Clinical Trial of Emiltatug Ledadotin (XMT-1660); Initiation of Expansion in Triple Negative Breast Cancer

GlobeNewswire January 10, 2025

Mersana Therapeutics Provides Business Update and Announces Third Quarter 2024 Financial Results

GlobeNewswire November 13, 2024

Mersana Therapeutics to Host Third Quarter 2024 Conference Call on November 13, 2024

GlobeNewswire November 6, 2024
View More News ››

Opinion & Analysis (NDAQ:MRSN)

Mersana Therapeutics Trades 60% Higher on Positive Phase 1 Ovarian Cancer Trial Data

Streetwise Reports May 28, 2020
View More Opinion ››

Bullboard Posts (NDAQ:MRSN)

Mersana Therapeutics to Host Fourth Quarter and Year End 202

News; $MRSN Mersana Therapeutics to Host Fourth Quarter and Year End 2024 Conference Call on March 3, 2025CAMBRIDGE, Mass., Feb. 24...
whytestocks - February 24, 2025

Mersana Therapeutics Provides Business Update and Announces

News; $MRSN Mersana Therapeutics Provides Business Update and Announces Third Quarter 2024 Financial ResultsPlan to announce initial...
whytestocks - November 13, 2024

Mersana Therapeutics to Host Third Quarter 2024 Conference C

Just In: $MRSN Mersana Therapeutics to Host Third Quarter 2024 Conference Call on November 13, 2024CAMBRIDGE, Mass., Nov. 06, 2024...
whytestocks - November 6, 2024
View more Bullboard ››

Diagnostear Technologies Inc

Diagnostear Technologies Inc

DiagnosTear is a leading ophthalmic company developing and commercializing disruptive diagnostic solutions for better ...
View More »